Mounting geopolitical tensions, evolving trade policies, regulatory reform, and structural changes in global health financing are reshaping the operating environment for pharmaceutical and biotech companies. Against this complex backdrop, growth expectations for healthcare spending and pharmaceutical sales are being recalibrated across major markets, says GlobalData, a leading intelligence and productivity platform.
To assess these developments, GlobalData Health Economics and Market Access team will host a webinar “Changes in the Operating Environment for the Pharma and Biotech Industries, and Outlook for 2026” on 10 March 2026 at 12:30 PM IST.
The speakers for the webinar include Milena Izmirlieva, Senior Director; Eóin Ryan, Manager; Cyrus Fan, Senior Research Analyst; Brendan Melck, Managing Analyst; Janet Beal, Managing Analyst; Leyla Hasanzadeh, Analyst; and Chia Lin, Senior Analyst.
The session will present the latest updates to GlobalData’s World Markets Healthcare (WMH) Forecast of health expenditure and pharmaceutical sales across 71 markets, highlighting revisions to healthcare spending and pharmaceutical sales projections. The team will examine the key drivers underpinning these changes, including pricing pressures, fiscal constraints, policy reforms, and innovation trends.
Additionally, the team will review early experiences with Joint Clinical Assessment (JCA) implementation in the European Union, alongside the implications of US tariff threats and persistent geopolitical uncertainty for healthcare budgets and pharmaceutical trade flows. The webinar will also explore the evolving US policy landscape, including updates on the Biosecure Act and the broader impact of actions by the Trump administration on healthcare provision and potential health outcomes.
Further analysis will address the emergence of a new era in health financing across low- and middle-income countries, particularly in Africa, following the US withdrawal from certain international initiatives. In parallel, the discussion will assess the accelerating growth of pharmaceutical innovation from China, Europe’s response to geopolitical shifts through domestic production reshoring, and the expanding use of compulsory licensing as governments seek to manage affordability pressures.
Izmirlieva comments: “The pharmaceutical operating environment is becoming more fragmented and politically sensitive. Policy divergence, fiscal tightening, and supply chain realignment are reshaping growth trajectories across markets. Companies must adapt strategies to manage pricing risk, regulatory uncertainty, and shifting risks to IP rights protection.”
The webinar will conclude with GlobalData’s outlook for the biopharmaceutical industry in 2026, providing actionable insights for manufacturers, investors, and policy stakeholders navigating an increasingly volatile global landscape.
Register now to secure your place for “Changes in the Operating Environment for the Pharma and Biotech Industries, and Outlook for 2026” webinar on 10 March 2026 at 12:30 PM IST.
